microRNA-137在神经胶质瘤中的作用机制

doi:10.3760/cma.j.issn.1007-1245.2022.13.029

摘要/Abstract

摘要： microRNA-137（miR-137，微小RNA-137）在许多肿瘤中特别是神经胶质瘤中表达异常，其通过靶向调节CDK6、Rac1、MRGBP、Notch1等基因以及PTP4A3、FOXK1基因介导的信号通路参与神经胶质瘤细胞的增殖、代谢、周期调控、侵袭及患者预后。该文章重点讨论miR-137在神经胶质瘤中的几种特殊的作用机制，进一步了解了miR-137的潜在功能，为神经胶质瘤的诊疗提供新思路。

关键词: miR-137, 神经胶质瘤, 靶基因

Abstract: MicroRNA-137 (miR-137) is abnormally expressed in many tumors, especially in gliomas. By targeting the regulation of CDK6, Rac1, MRGBP, Notch1, and other genes, as well as the signaling pathways mediated by PTP4A3 and FOXK1 genes, it participates in the proliferation, metabolism, cycle regulation, and invasion of glioma cells and patient prognosis. This paper focuses on several specific mechanisms of action of miR-137 in gliomas, so as to understand the potential functions of miR-137 and provide new ideas for the diagnosis and treatment of gliomas.

Key words: miR-137, Glioma, Targeted genes

王宁宁朱淑霞. microRNA-137在神经胶质瘤中的作用机制[J]. 国际医药卫生导报, 2022, 28(13): 1916-1919.

Wang Ningning, Zhu Shuxia. Mechanism of action of microRNA-137 in gliomas[J]. International Medicine and Health Guidance News, 2022, 28(13): 1916-1919.

参考文献

[1] Alamoudi AA, Alnoury A, Gad H. miRNA in tumour metabolism and why could it be the preferred pathway for energy reprograming [J]. Brief Funct Genomics, 2018, 17(3):157-169. DOI: 10.1093/bfgp/elx023.
[2] Duffy CP, McCoy CE. The role of microRNAs in repair processes in multiple sclerosis [J]. Cells, 2020, 9(7):1711. DOI: 10.3390/cells9071711.
[3] Liu X, Chen L, Tian XD, et al. MiR-137 and its target TGFA modulate cell growth and tumorigenesis of non-small cell lung cancer [J]. Eur Rev Med Pharmacol Sci, 2017, 21(3): 511-517.
[4] Chu PC, Lin PC, Wu HY, et al. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway [J]. Oncogene, 2018, 37(25): 3440-3455. DOI: 10.1038/s41388-018-0222-3.
[5] Liu C, Wu H, Li Y, et al. SALL4 suppresses PTEN expression to promote glioma cell proliferation via PI3K/AKT signaling pathway [J]. J Neurooncol, 2017, 135(2):263-272. DOI: 10.1007/s11060-017-2589-3.
[6] Wu M, Wang J, Tang W, et al. FOXK1 interaction with FHL2 promotes proliferation, invasion and metastasis in colorectal cancer [J]. Oncogenesis, 2016, 5(11):e271. DOI: 10.1038/oncsis.2016.68.
[7] Wu SH, Bi JF, Cloughesy T, et al. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance [J]. Cancer Biol Med, 2014, 11(4):255-263. DOI: 10.7497/j.issn.2095-3941. 2014.04.004.
[8] Neil J, Shannon C, Mohan A, et al. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma [J]. Int J Oncol, 2016, 48(3):1045-1052. DOI: 10.3892/ijo.2015.3311.
[9] Li X, Wu C, Chen N, et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma [J]. Oncotarget, 2016, 7(22): 33440 -33450. DOI: 10.18632/oncotarget.7961.
[10] Wang L, Liu J, Zhong Z, et al. PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137[J]. Brain Res, 2016,1646: 441-450. DOI:10.1016/j.brainres.2016.06.026.
[11] Zhu H. Forkhead box transcription factors in embryonic heart development and congenital heart disease [J]. Life Sci, 2016, 144: 194-201. DOI: 10.1016/j.lfs.2015.12.001.
[12] Wu M, Wang J, Tang W, et al. FOXK1 interaction with FHL2 promotes proliferation, invasion and metastasis in colorectal cancer [J]. Oncogenesis, 2016, 5(11): e271. DOI: 10.1038/oncsis.2016.68.
[13] Wu M, Wang J, Tang W, et al. FOXK1 interaction with FHL2 promotes proliferation, invasion and metastasis in colorectal cancer [J]. Oncogenesis, 2016,5(11):e271. DOI: 10.1038/oncsis.2016.68.
[14] Gao L, Chen B, Li J, et al. Wnt/β-catenin signaling pathway inhibits the proliferation and apoptosis of U87 glioma cells via different mechanisms [J]. PLoS One, 2017,12(8):e0181346. DOI: 10.1371/journal.pone.0181346.
[15] Ji ZG, Jiang HT, Zhang PS. FOXK1 promotes cell growth through activating wnt/β-catenin pathway and emerges as a novel target of miR-137 in glioma [J]. Am J Transl Res, 2018, 10(6):1784-1792.
[16] 谢渊,李抄,张晓怡,等. 胃泌素对胃癌细胞EMT和Wnt/β-catenin信号通路相关基因表达的影响[J]. 中国老年学杂志,2021,41(2):338-342. DOI:10.3969/j.issn.1005-9202. 2021.02.033.
[17] Wang W, Li X, Lee M, et al. FOXKs promote Wnt/β-catenin signaling by translocating DVL into the nucleus [J]. Dev Cell, 2015, 32(6):707-718. DOI: 10.1016/j.devcel.2015. 01.031.
[18] Gu X, Yao L, Ma G, et al. TCTP promotes glioma cell proliferation in vitro and in vivo via enhanced β-catenin/TCF-4 transcription [J]. Neuro Oncol, 2014, 16(2):217-227. DOI: 10.1093/neuonc/not194.
[19] Cao Y, Li X, Kong S, et al. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells[J]. J Cell Mol Med, 2020, 24(9):5135-5145. DOI: 10.1111/jcmm.15156.
[20] Moradimotlagh A, Arefian E, Rezazadeh VR, et al. MicroRNA-129 Inhibits Glioma Cell Growth by Targeting CDK4, CDK6, and MDM2[J]. Mol Ther Nucleic Acids, 2020, 19: 759-764.DOI: 10.1016/j.omtn.2019.11.033
[21] Bhaskaran V, Nowicki MO, Idriss M, et al. The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma [J]. Nat Commun, 2019, 10(1):442. DOI: 10.1038/s41467-019-08390-z.
[22] Fortin ES, Mathews IT, Symons MH, et al. Implications of Rho GTPase signaling in glioma cell invasion and tumor progression[J]. Front Oncol, 2013, 3: 241. DOI: 10.3389/fonc.2013.00241.
[23] Kopfer KH, Jager W, Matthaus F. A mechanochemical model for rho GTPase mediated cell polarization [J]. J Theor Biol, 2020, 504: 110386. DOI: 10.1016/j.jtbi.2020.110386.
[24] Liang Z, Li J, Zhao L, et al. miR-375 affects the hedgehog signaling pathway by downregulating RAC1 to inhibit hepatic stellate cell viability and epithelial-mesenchymal transition [J]. Mol Med Rep, 2021, 23(3):182. DOI: 10.3892/mmr.2020.11821.
[25] Liu Y, Lu Y, Li A, et al. mTORC2/Rac1 pathway predisposes cancer aggressiveness in IDH1-mutated glioma [J]. Cancers (Basel), 2020, 12(4):787. DOI: 10.3390/cancers12040787.
[26] Qin W, Rong X, Dong J, et al. miR-142 inhibits the migration and invasion of glioma by targeting Rac1[J]. Oncol Rep, 2017, 38(3): 1543-1550. DOI: 10.3892/or.2017.5816.
[27] Rivero S, Rodríguez-Real G, Marín I, et al. MRGBP, a member of the NuA4 complex, inhibits DNA double-strand break repair [J]. FEBS Open Bio, 2021, 11(3):622-632. DOI: 10.1002/2211-5463.13071.
[28] Huang J, Chen X, Zhu W. MRGBP is a potential novel prognostic biomarker and is correlated with immune infiltrates in hepatocellular carcinoma [J]. Medicine (Baltimore), 2021, 100(12):e25234. DOI: 10.1097/MD.0000000000025234.
[29] Ding F, Zhang S, Gao S, et al. MRGBP as a potential biomarker for the malignancy of pancreatic ductal adenocarcinoma [J]. Oncotarget, 2017, 8(38): 64224- 64236. DOI: 10.18632/oncotarget.19451.
[30] Chai D, Zhang L, Guan Y, et al. Prognostic value and immunological role of MORF4-related gene-binding protein in human cancers [J]. Front Cell Dev Biol, 2021, 9:703415. DOI: 10.3389/fcell.2021.703415.
[31] Ding F, Zhang S, Gao S, et al. MiR-137 functions as a tumor suppressor in pancreatic cancer by targeting MRGBP [J]. J Cell Biochem, 2018, 119(6): 4799-4807. DOI: 10.1002/jcb.26676.
[32] Shi X, Wang R. Glioma cell fate decisions mediated by Dll1-Jag1-Fringe in Notch1 signaling pathway [J]. BMC Syst Biol, 2017, 11 Suppl 4:84. DOI: 10.1186/s12918-017-0457-6.
[33] Liu PJ, Pan YH, Wang DW, et al. Long non-coding RNA XIST promotes cell proliferation of pancreatic cancer through miR-137 and Notch1 pathway [J]. Eur Rev Med Pharmacol Sci, 2020,24(23):12161-12170. DOI: 10.26355/eurrev_202012_24005.